Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 17,842 matching trials from the live ClinicalTrials.gov search.
Conditions
Pediatric ALL
Interventions
ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
Up to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Orange, California • San Diego, California • Louisville, Kentucky + 2 more
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Neuroblastoma
Interventions
carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation, Mild Alzheimer's Disease
Interventions
Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Gastroesophageal Reflux
Interventions
Metaclopramide, Ranitidine, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Month to 6 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Conditions
Congenital Heart Disease, SRV Dependent
Interventions
Autologous mononuclear cells
Biological
Lead sponsor
Timothy J Nelson, MD, PhD
Other
Eligibility
2 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Conditions
Neuroblastoma
Interventions
Hu3F8 With GM-CSF
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Clostridium Difficile
Interventions
C. difficile vaccine with adjuvant, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Varenicline on Cigarette Self Administration

NCT00731055
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Mucopolysaccharidosis I
Interventions
AGT-181 (HIRMAb-IDUA)
Drug
Lead sponsor
ArmaGen, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Oakland, California • Orange, California • Decatur, Georgia + 3 more
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more
Completed Phase 1 Interventional Results available

Assessment of KAN-101 in Celiac Disease (ACeD)

NCT04248855
Conditions
Celiac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Anaheim, California • Walnut Creek, California • Aventura, Florida + 10 more
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Conditions
Hereditary Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of Filler Injection for Chin Profile Enhancement

NCT07777926
Conditions
Chin Regression, Chin Asymmetry, Jawline Contour Deficit
Interventions
HA Filler
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Myelodysplastic Syndrome
Interventions
Clofarabine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 2 Interventional Results available

6-week Safety and PD Study in Adults With NAFLD

NCT03256526
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06835919 Low Dose, PF-06835919 High Dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • DeLand, Florida • Miami, Florida + 6 more
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Conditions
Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Trastuzumab Deruxtecan, Datopotamab Deruxtecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more
Conditions
Chronic Kidney Failure
Interventions
Magnesium iron hydroxycarbonate, Lanthanum carbonate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 56 more